Brodalumab: Phase III started

AstraZeneca disclosed in its 3Q12 earnings that enrollment began in the double-blind, international Phase III AMAGINE-1, -2 and -3 trials evaluating 140 and 210 mg subcutaneous brodalumab. AMAGINE-1 will enroll about 600 patients to compare brodalumab vs. placebo for 12 weeks. After 12 weeks, patients in the brodalumab arms will be re-randomized to receive placebo or continue treatment. AMAGINE-2 and -3 will each enroll about 1,800 patients to compare brodalumab vs. 45 or 90 mg ustekinumab or placebo for 12 weeks. After 12 weeks, patients in the brodalumab arms will be re-randomized to 1 of 4 treatment schedules. Patients who received placebo in the 12-week period in the 3 trials will thereafter be assigned 210 mg brodalumab. ...